## Supplemental Tables

## Supplemental Table 1. Clinico-pathological characteristics of the patients and their tumours included in the colorectal cancer tissue microarray

|  | Percent (number) | Relationship with survival |
| :---: | :---: | :---: |
| Sex |  |  |
| Male | 52\% (340) | $\chi^{2}=0.049 ; p=0.825$ |
| Female | 48\% (310) |  |
| Age (mean:range) | (69:24-94) |  |
| $<70$ | 47\% (305) | $\chi^{2}=21.99 ; p<0.001$ |
| $\geq 70$ | 53\% (345) |  |
| Tumor site* |  |  |
| Proximal | 40\% (261) | proximal v distal, $\chi^{2}=8.723 ; p=0.003$ |
| Distal | 38\% (245) | proximal v rectum, $\chi^{2}=2.089 ; p=0.148$ |
| Rectum | 22\% (144) | distal $v$ rectum, $\chi^{2}=0.976 ; p=0.323$ |
| Tumor differentiation |  |  |
| Well/Moderate | 92\% (600) | $\chi^{2}=2.259 ; p=0.133$ |
| Poor | 8\% (50) |  |
| Extra-mural vascular invasion |  |  |
| Present | 16.6\% (93) | $\chi^{2}=93.26 ; p<0.001$ |
| Absent | 83.4\% (468) |  |
| p T stage |  |  |
| T1 | 4.6 \% (30) | T1 v T2, $\chi^{2}=1.217 ; p=0.270$ |
| T2 | 17.5\% (114) | T2 v T3, $\chi^{2}=26.908 ; p<0.001$ |
| T3 | 63.2\% (411) | T3 v T4, $\chi^{2}=34.144 ; p<0.001$ |
| T4 | 14.6\% (95) |  |
| pN stage |  |  |
| NO | 56.2\% (365) | N0 v N1, $\chi^{2}=68.273 ; p<0.001$ |
| N1 | 27.1\% (176) | N1 v N2, $\chi^{2}=13.257$; $p<0.001$ |
| N2 | 16.8\% (109) |  |
| Stage (AJCC stage) |  |  |
| Stage 1 | 18.5\% (120) | stage 1 v stage 2, $\chi^{2}=6.503 ; p=0.011$ |
| Stage 2 | 37.7\% (245) | stage 2 v stage $3, \chi^{2}=70.647 ; p<0.001$ |
| Stage 3 | 43.8\% (285) |  |
| Stage |  |  |
| Dukes A | 18.5\% (120) | Dukes A v Dukes B, $\chi^{2}=6.503 ; p=0.011$ |
| Dukes B | 37.7\% (245) | Dukes B v Dukes C, $\chi^{2}=70.647 ; p<0.001$ |
| Dukes C | 43.8\% (285) |  |

*Proximal colon tumors arose proximal to the splenic flexure (i.e. cecum, ascending colon, transverse colon) while distal colon tumors arose distal to this point (i.e. splenic flexure, descending colon and sigmoid colon).

Supplemental Table 2. Dunn's multiple comparison results for statistical significant differences in ranked LIMK2 staining

|  | Dukes A | Dukes B | Dukes C | Lymph Node |
| :---: | :---: | :---: | :---: | :---: |
| Normal | $\mathrm{p}<0.05$ | $\mathrm{p}<0.001$ | $\mathrm{p}<0.001$ | $\mathrm{p}<0.001$ |
| Dukes A |  | $\mathrm{p}<0.001$ | $\mathrm{p}<0.001$ | $\mathrm{p}<0.001$ |
| Dukes B |  |  | $\mathrm{p}<0.01$ | $\mathrm{p}<0.01$ |
| Dukes C |  |  |  | NS |

NS = not significant

Supplemental Table 3. Estimated mean and median survival times for low and high LIMK2 expressing patients

| LIMK2 | Total | N of <br> events | Censored |  | Estimated <br> Mean Survival <br> (months) | Estimated <br> Median <br> Survival <br> (months) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | N | Percent |  |  |
| Staining | N |  |  |  |  |  |
| Rank |  |  |  |  |  |  |
| Low (1-3) | 298 | 145 | 153 | 51.3\% | 93.9 | 72.0 |
| High (4-6) | 323 | 110 | 213 | 65.9\% | 118.2 | 156.0 |
| Overall | 621 | 255 | 366 | 58.9\% | 108.1 | 93.0 |

Supplemental Table 4. Estimated mean and median survival times for each patient LIMK2 stain ranking.

|  |  |  | Censored |  | Estimated <br> Mean Survival <br> (months) | Estimated <br> Median Survival <br> (months) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| LIMK2 <br> Staining | Total <br> N | $N$ of events | N | Percent |  |  |
| Rank |  |  |  |  |  |  |
| 1 | 38 | 20 | 18 | 47.4\% | 74.9 | 70.0 |
| 2 | 133 | 70 | 63 | 47.4\% | 87.5 | 62.0 |
| 3 | 127 | 55 | 72 | 56.7\% | 102.6 | 83.0 |
| 4 | 171 | 66 | 105 | 61.4\% | 109.9 | 113.0 |
| 5 | 128 | 40 | 88 | 68.8\% | 115.2 | - |
| 6 | 24 | 4 | 20 | 83.3\% | 142.7 | - |
| Overall | 621 | 255 | 366 | 58.9\% | 108.1 | 93 |

Supplemental Table 5. Dunn's multiple comparison results for statistical significant differences in ranked pCFL staining

|  | Dukes A | Dukes B | Dukes C | Lymph Node |
| :---: | :---: | :---: | :---: | :---: |
| Normal | $\mathrm{p}<0.001$ | $\mathrm{p}<0.001$ | $\mathrm{p}<0.001$ | $\mathrm{p}<0.001$ |
| Dukes A |  | NS | $\mathrm{p}<0.001$ | $\mathrm{p}<0.001$ |
| Dukes B |  |  | $\mathrm{p}<0.01$ | $\mathrm{p}<0.01$ |
| Dukes C |  |  |  | NS |

NS = not significant

Supplemental Table 6. Estimated mean and median survival times for low and high pCFL expressing patients

| pCFL | Total | N of | Censored |  | Estimated | Estimated |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | Percent | Mean Survival | Median Survival |
| Rank |  |  |  |  |  |  |
| (months) | (months) |  |  |  |  |  |
| Low (1-3) | 299 | 150 | 159 | $49.8 \%$ | 91.2 | 72.0 |
| High (4-6) | 282 | 95 | 187 | $66.3 \%$ | 119.3 | 115.0 |
| Overall | 581 | 245 | 336 | $57.8 \%$ | 106.4 | 84.0 |

Supplemental Table 7. Estimated mean and median survival times for each patient pCFL stain ranking.

|  |  | N of <br> events | Censored |  | Estimated <br> Mean Survival <br> (months) | Estimated <br> Median Survival <br> (months) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| pCFL <br> Staining | Total <br> N |  | N | Percent |  |  |
| Rank |  |  |  |  |  |  |
| 1 | 60 | 33 | 27 | 44.0\% | 86.5 | 64.0 |
| 2 | 142 | 71 | 71 | 50.0\% | 88.1 | 75.0 |
| 3 | 97 | 46 | 51 | 52.6\% | 84.7 | 67.0 |
| 4 | 141 | 55 | 86 | 61.0\% | 99.3 | 107.0 |
| 5 | 83 | 26 | 57 | 68.7\% | 123.5 | 113.0 |
| 6 | 2458 | 14 | 44 | 75.9\% | 140.8 | - |
| Overall | 581 | 255 | 336 | 57.8\% | 106.4 | 84 |

Supplemental Table 8. Estimated mean and median survival times for combinations of High and Low LIMK2 and pCFL stain ranking.

| pCFL | LIMK2 | Total $\mathbf{N}$ | N of events | Censored |  | Estimated <br> Mean <br> Survival <br> Time | Estimated <br> Median <br> Survival <br> Time |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | N | Percent |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
| Low | Low | 207 | 112 | 95 | 45.9\% | 84.6 | 63.0 |
|  | High | 86 | 33 | 53 | 61.6\% | 102.4 | 124.0 |
|  | Overall | 293 | 145 | 148 | 50.5\% | 92.4 | 75.0 |
| High | Low | 58 | 22 | 36 | 62.1\% | 107.3 | 84.0 |
|  | High | 222 | 73 | 149 | 67.1\% | 118.9 | 115.0 |
|  | Overall | 280 | 95 | 185 | 66.1\% | 119.0 | 115.0 |
| Overall |  | 573 | 240 | 333 | 58.1\% | 107.0 | 88.0 |

